- Home
- CUE vs YI Comparison
CUE vs YI Comparison
Compare CUE & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | YI |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 38.1M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CUE | YI |
|---|---|---|
| Price | $0.54 | $3.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 361.2K | 11.5K |
| Earning Date | 11-12-2025 | 12-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,100,000.00 | ★ $1,979,883,442.00 |
| Revenue This Year | $36.58 | N/A |
| Revenue Next Year | $32.10 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $3.19 |
| 52 Week High | $1.75 | $11.35 |
Technical Indicators
Market Signals| Indicator | CUE | YI |
|---|---|---|
| Relative Strength Index (RSI) | 34.41 | 40.75 |
| Support Level | $0.55 | $3.60 |
| Resistance Level | $0.66 | $3.88 |
| Average True Range (ATR) | 0.05 | 0.19 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 13.24 | 69.51 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.